Document is current
Any future updates will be listed below
-
Authors
Antel, Jochen
Gradl-Dietsch, Gertraud
Peters, Triinu
Pridzun, Lutz
Degenhardt, Franziska
von Piechowski, Linda
Hinney, Anke
Hebebrand, Johannes
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 25 June 2025
First Online: 5 July 2025
Declarations
:
: Both the patient and her parents provided written informed consent to participate in the study and to the publication of the case report including the supplemental texts provided by T Due to German law ethics approval is not applicable for an off-label application of an otherwise approved drug in an individual patient.
: Johannes Hebebrand, Gertraud Gradl-Dietsch, and Jochen Antel declare that they were named as inventors in a patent application that the University of Duisburg-Essen filed on the use of leptin analogues for the treatment of depression. Johannes Hebebrand and Jochen Antel declare that they were named as inventors in two patent applications that the University of Duisburg-Essen had filed on the use of leptin analogues for treating anorexia nervosa and atypical anorexia nervosa. Johannes Hebebrand received speaker’s honoraria from Amryt Pharmaceuticals and Novo-Nordisk. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
